WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today ...
C4 Therapeutics has begun dosing in a Phase Ib study assessing cemsidomide and elranatamab (Elrexfio) in patients with relapsed or refractory multiple myeloma (r/r MM). The multi-centre, open-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results